Largest-ever Psychedelics Study Could Advance Use in Treating Mental Health Disorders
The largest psychedelic research mental health study marks a critical step toward evidence-based psychiatric care. This large-scale study aims to identify which patients benefit most from psychedelics. It could establish standardized protocols for…
Here’s What Psychedelics Actually Do to the Brain
Psychedelics neuropharmacology mental health research is advancing as these compounds enter clinical trials for treatment-resistant conditions. Understanding their brain effects is crucial for clinicians counseling patients. This emerging field offers…
Medical Marijuana’s Growing Role in Clinical Trials
Medical cannabis clinical trials are increasing, marking a shift toward evidence-based cannabis medicine. This growth supports clinicians in making informed treatment decisions. The focus on rigorous trials enhances understanding of cannabis’s…
CU Boulder and CSU Collaborate to Share Cannabis Research Facilities
Academic research partnerships cannabis between CU Boulder and CSU are set to accelerate cannabis research by pooling resources and expertise. This collaboration addresses long-standing infrastructure gaps in cannabis clinical research. Such partnerships…
How Marijuana Rescheduling Could Unlock Research for Rare Diseases
Marijuana rescheduling research regulatory shift would remove key barriers to clinical trials for rare pediatric diseases. This change enables rigorous studies that families and clinicians have long awaited. It is a critical step toward evidence-based…
Missouri Bill Would Allow Clinical Trials on Psychedelic Therapy for Veterans, First Responders
Missouri's new bill enables psychedelic-assisted therapy clinical trials specifically for veterans and first responders. These clinical trials aim to generate rigorous safety and efficacy data. Psychedelic-assisted therapy clinical trials represent a…
Dietary Bioactives in Alzheimer’s Disease: A Critical Appraisal of Clinical Trials and Future Directions
This review critically examines dietary bioactives alzheimer s disease clinical trials, focusing on cannabinoids and other compounds. It provides clinicians with an evidence-based assessment to distinguish promising treatments from marketing claims.…
Quantum Biopharma Seeks FDA Clearance for Lucid-MS Phase 2 Trial
Quantum Biopharma is advancing a cannabis-based therapeutic phase 2 trial for Lucid-MS. This trial targets cognitive symptoms in multiple sclerosis patients. The phase 2 trial is a critical step to evaluate efficacy beyond safety.
Exploring Neuroprotective Cannabis Clinical Trials and Their Impact
Neuroprotective cannabis clinical trials are advancing research into treatments for neurological disorders. These trials explore cannabis compounds' potential to protect nerve cells. Understanding clinical evidence helps guide safe and effective use.
Experimental Cannabis Extract Shows Promise for Chronic Back Pain
An experimental cannabis extract chronic back pain trial has shown promising results in reducing symptoms. This research adds valuable clinical evidence for cannabis in pain management. Patients with chronic back pain may benefit from emerging cannabis…
